Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density

Jeroen Walpot; Paul Van Herck; Caroline M. Van de Heyning; Johan Bosmans; Samia Massalha; João R. Inácio; Hein Heidbuchel; Manu L. Malbrain

doi:10.5114/ait.2023.132460

eISSN: 1731-2531
ISSN: 1642-5758

Anaesthesiology Intensive Therapy

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Open access

Journal integrated with

4/2023
vol. 55

Send email

Copy url:

abstract:

Special paper

Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density

Jeroen Walpot

¹

,

Paul Van Herck

^{2, 3}

,

Caroline M. Van de Heyning

^{2, 3}

,

Johan Bosmans

^{2, 3}

,

Samia Massalha

⁴

,

João R. Inácio

⁵

,

Hein Heidbuchel

^{2, 3}

,

Manu L. Malbrain

^{6, 7}

Zorgsaam Hospital, Netherlands
Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium
Cardiovascular Sciences, University of Antwerp, Antwerp, Belgium
Rambam Health Campus, Haifa, Israel
Centro Hospitalar Universitário Lisboa Norte/ Hospital de Santa Maria, Lisbon, Portugal
International Fluid Academy, Lovenjoel, Belgium
First Department of Anaesthesiology and Intensive Therapy, Medical University of Lublin, Lublin, Poland

Anaesthesiol Intensive Ther 2023; 55, 4: 243-261

DOI: https://doi.org/10.5114/ait.2023.132460

Online publish date: 2023/11/14

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Walpot J, Van Herck P, Van de Heyning C, et al. Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density. Anaesthesiology Intensive Therapy. 2023;55(4):243-261. doi:10.5114/ait.2023.132460.

APA

Walpot, J., Van Herck, P., Van de Heyning, C., Bosmans, J., Massalha, S.,  & Inácio, J. et al. (2023). Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density. Anaesthesiology Intensive Therapy, 55(4), 243-261. https://doi.org/10.5114/ait.2023.132460

Chicago

Walpot, Jeroen, Paul Van Herck, Caroline M. Van de Heyning, Johan Bosmans, Samia Massalha, João R. Inácio,  and Hein Heidbuchel et al. 2023. "Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density". Anaesthesiology Intensive Therapy 55 (4): 243-261. doi:10.5114/ait.2023.132460.

Harvard

Walpot, J., Van Herck, P., Van de Heyning, C., Bosmans, J., Massalha, S., Inácio, J., Heidbuchel, H.,  and L. Malbrain, M. (2023). Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density. Anaesthesiology Intensive Therapy, 55(4), pp.243-261. https://doi.org/10.5114/ait.2023.132460

MLA

Walpot, Jeroen et al. "Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density." Anaesthesiology Intensive Therapy, vol. 55, no. 4, 2023, pp. 243-261. doi:10.5114/ait.2023.132460.

Vancouver

Walpot J, Van Herck P, Van de Heyning C, Bosmans J, Massalha S, Inácio J et al. Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality  in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density. Anaesthesiology Intensive Therapy. 2023;55(4):243-261. doi:10.5114/ait.2023.132460.

PlumX metrics:

Sarcopenia is a syndrome characterised by loss of skeletal muscle mass, loss of muscle quality, and reduced muscle strength, resulting in low performance. Sarcopenia has been associated with increased mortality and complications after medical interventions.

In daily clinical practice, sarcopenia is assessed by clinical assessment of muscle strength and performance tests and muscle mass quantification by dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA).

Assessment of the skeletal muscle quantity and quality obtained by abdominal computed tomography (CT) has gained interest in the medical community, as abdominal CT is performed for various medical reasons, and quantification of the psoas and skeletal muscle can be performed without additional radiation load and dye administration.

The definitions of CT-derived skeletal muscle mass quantification are briefly reviewed: psoas muscle area (PMA), skeletal muscle area (SMA), and transverse psoas muscle thickness (TPMT).

We explain how CT attenuation coefficient filters are used to determine PMA and SMA, resulting in the psoas muscle index (PMI) and skeletal muscle index (SMI), respectively, after indexation to body habitus.

Psoas muscle density (PMD), a biomarker for skeletal muscle quality, can be assessed by measuring the psoas muscle CT attenuation coefficient, expressed in Hounsfield units. The concept of low-density muscle (LDM) is explained.

Finally, we review the medical literature on PMI and PMD as predictors of adverse outcomes in patients undergoing trauma or elective major surgery, transplantation, and in patients with cardiovascular and internal disease. PMI and PMD are promising new biomarkers predicting adverse outcomes after medical interventions.

keywords:

biomarkers, sarcopenia, computed tomography, psoas muscle area (PMA), psoas muscle density (PMD), major acute cardiovascular events (MACE), postoperative clinical outcomes

Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events and mortality in patients with heart disease and critically ill patients. Part II: Psoas muscle area and density

Jeroen Walpot 1 , Paul Van Herck 2, 3 , Caroline M. Van de Heyning 2, 3 , Johan Bosmans 2, 3 , Samia Massalha 4 , João R. Inácio 5 , Hein Heidbuchel 2, 3 , Manu L. Malbrain 6, 7

biomarkers, sarcopenia, computed tomography, psoas muscle area (PMA), psoas muscle density (PMD), major acute cardiovascular events (MACE), postoperative clinical outcomes

Jeroen Walpot

¹

,

Paul Van Herck

^{2, 3}

,

Caroline M. Van de Heyning

^{2, 3}

,

Johan Bosmans

^{2, 3}

,

Samia Massalha

⁴

,

João R. Inácio

⁵

,

Hein Heidbuchel

^{2, 3}

,

Manu L. Malbrain

^{6, 7}